Giant Axonal Neuropathy (GAN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Giant Axonal Neuropathy (GAN) Market Outlook

Thelansis’s “Giant Axonal Neuropathy (GAN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Giant Axonal Neuropathy (GAN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Giant Axonal Neuropathy (GAN) Overview

Giant Axonal Neuropathy (GAN) is a rare autosomal recessive neurodegenerative disorder impacting both the central and peripheral nervous systems, typically characterized by progressive weakness and ataxia. Alongside these symptoms, individuals experience sensory loss and eventual loss of ambulation, often leading to respiratory failure. The condition stems from an anomaly within the GAN gene, found on chromosome 16 at 16q24.1, responsible for encoding the gigaxonin protein. This abnormal protein results in the swelling of axons, where tiny thread-like deposits of neurofilaments accumulate, creating the appearance of giant axons. Consequently, this leads to degeneration and dysfunctional activity within the peripheral nervous system. Neuropathological investigations have revealed a loss of gigaxonin expression affecting regions such as the cerebellar cortex, brainstem, and posterior columns of the spinal cord. Consequently, this disorder is considered a promising candidate for intrathecal delivery of AAV9 gene transfer, aiming to restore gigaxonin function. Gigaxonin plays a crucial role in organizing and degrading intermediate filaments. Thus, its absence leads to axonal enlargement characterized by densely bundled intermediate filaments. Standard features of Giant Axonal Neuropathy include hypotonia (low muscle tone), muscle weakness, diminished reflexes, ataxia, seizures, and intellectual disability. Regrettably, there are currently no FDA-approved treatments for GAN. Management primarily revolves around counseling and symptomatic approaches, including bracing, physical therapy, aquatic therapy, and pain management.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Giant Axonal Neuropathy (GAN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034